Exploring CSL and Pro Medicus: A Closer Look at ASX 200 Healthcare Standouts

3 min read | June 27, 2025 11:28 AM AEST | By Team Kalkine Media

Google News:

Exploring CSL and Pro Medicus: A Closer Look at ASX 200 Healthcare Standouts — Image source: shutterstock

Recent News

Santos (ASX:STO) After the Takeover Collapse: Bargain or Value Trap?

Why Pro Medicus (ASX:PME) Is Leading the Growth Stock Conversation

Is 360 (ASX:360) Amid ASX 200 Revealing Growth’s New Reality?

Why 360 (ASX:360) ASX 200 Is Facing a New Growth Test

Make Kalkine Media
My Trusted Source

Highlights

CSL (CSL) share price has dropped since early 2025

Pro Medicus (PME) continues to trade significantly above 52-week lows

Both companies hold key roles in the ASX 200 healthcare sector

Investors and market watchers eyeing the ASX 200 healthcare segment have seen two significant players—CSL Limited (CSL) and Pro Medicus (PME)—attracting interest for different reasons. While one navigates a valuation reset, the other continues its strong momentum from a low base.

CSL Limited (ASX:CSL): A Long-Term Healthcare Innovator

CSL, a global biotechnology powerhouse, has seen its share price soften by 14.7% since the beginning of 2025. Though it originated as a government entity, the company now spans across three key business divisions—CSL Behring, CSL Seqirus, and CSL Vifor.

CSL Behring develops and markets plasma-derived therapies, often used to treat immune deficiencies and bleeding disorders. Seqirus focuses on influenza vaccines and pandemic response solutions, while Vifor addresses iron deficiency and kidney-related conditions.

The company has built a solid track record of consistent dividend payments over decades, adding to its appeal in a market segment that is generally viewed as resilient. For income-focused participants, CSL currently offers a dividend yield of approximately 1.65%, marginally higher than its five-year average of 1.50%. This slight uptick may reflect a combination of growing dividend payouts and recent share price adjustments. Notably, its latest annual report indicates that the dividend has increased compared to its three-year average, reinforcing its reputation as a stable contributor within the ASX 200.

Pro Medicus (ASX:PME): A Digital Health Growth Story

In contrast to CSL's size and maturity, Pro Medicus brings a tech-driven narrative to the healthcare sector. Established in 1983, it delivers advanced radiology IT solutions—including Radiology Information Systems (RIS), Picture Archiving and Communication Systems (PACS), and visualization tools used globally by hospitals and imaging centers.

PME’s share price is currently trading a substantial 129.1% above its 52-week low, demonstrating robust investor sentiment. Its valuation reflects high growth expectations, evident in its price-to-sales ratio of 179.64x—well above its five-year average of 82.69x. While this suggests a premium, it also underscores the market’s confidence in the company’s scalable technology and expansion prospects.

Both CSL and Pro Medicus hold distinct positions within the ASX 200 framework. CSL brings long-term consistency and essential pharmaceutical innovation, while Pro Medicus reflects the growing role of software and data in modern healthcare delivery. Whether the interest lies in healthcare stability or tech-enabled medical solutions, these companies illustrate the diversity within the ASX 200 healthcare landscape.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.